Cargando…
L-isoleucine-supplemented Oral Rehydration Solution in the Treatment of Acute Diarrhoea in Children: A Randomized Controlled Trial
Antimicrobial peptides represent an important component of the innate immune defenses of living organisms, including humans. They are broad-spectrum surface-acting agents secreted by the epithelial cells of the body in response to infection. Recently, L-isoleucine and its analogues have been found t...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
International Centre for Diarrhoeal Disease Research, Bangladesh
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3131118/ https://www.ncbi.nlm.nih.gov/pubmed/21766553 |
_version_ | 1782207689651126272 |
---|---|
author | Alam, N.H. Raqib, R. Ashraf, H. Qadri, F. Ahmed, S. Zasloff, M. Agerberth, B. Salam, M.A. Gyr, N. Meier, R. |
author_facet | Alam, N.H. Raqib, R. Ashraf, H. Qadri, F. Ahmed, S. Zasloff, M. Agerberth, B. Salam, M.A. Gyr, N. Meier, R. |
author_sort | Alam, N.H. |
collection | PubMed |
description | Antimicrobial peptides represent an important component of the innate immune defenses of living organisms, including humans. They are broad-spectrum surface-acting agents secreted by the epithelial cells of the body in response to infection. Recently, L-isoleucine and its analogues have been found to induce antimicrobial peptides. The objectives of the study were to examine if addition of L-isoleucine to oral rehydration salts (ORS) solution would reduce stool output and/or duration of acute diarrhoea in children and induce antimicrobial peptides in intestine. This double-blind randomized controlled trial was conducted at the Dhaka Hospital of ICDDR,B. Fifty male children, aged 6-36 months, with acute diarrhoea and some dehydration, attending the hospital, were included in the study. Twenty-five children received L-isoleucine (2 g/L)-added ORS (study), and 25 received ORS without L-isoleucine (control). Stool weight, ORS intake, and duration of diarrhoea were the primary outcomes. There was a trend in reduction in mean±standard deviation (SD) daily stool output (g) of children in the L-isoleucine group from day 2 but it was significant on day 3 (388±261 vs 653±446; the difference between mean [95% confidence interval (CI) (-)265 (−509, −20); p=0.035]. Although the cumulative stool output from day 1 to day 3 reduced by 26% in the isoleucine group, it was not significant. Also, there was a trend in reduction in the mean±SD intake of ORS solution (mL) in the L-isoleucine group but it was significant only on day 1 (410±169 vs 564±301), the difference between mean (95% CI) (-)154 (-288, −18); p=0.04. The duration (hours) of diarrhoea was similar in both the groups. A gradual increase in stool concentrations of ß-defensin 2 and 3 was noted but they were not significantly different between the groups. L-isoleucine-supplemented ORS might be beneficial in reducing stool output and ORS intake in children with acute watery diarrhoea. A further study is warranted to substantiate the therapeutic effect of L-isoleucine. |
format | Online Article Text |
id | pubmed-3131118 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | International Centre for Diarrhoeal Disease Research, Bangladesh |
record_format | MEDLINE/PubMed |
spelling | pubmed-31311182011-08-16 L-isoleucine-supplemented Oral Rehydration Solution in the Treatment of Acute Diarrhoea in Children: A Randomized Controlled Trial Alam, N.H. Raqib, R. Ashraf, H. Qadri, F. Ahmed, S. Zasloff, M. Agerberth, B. Salam, M.A. Gyr, N. Meier, R. J Health Popul Nutr Original Papers Antimicrobial peptides represent an important component of the innate immune defenses of living organisms, including humans. They are broad-spectrum surface-acting agents secreted by the epithelial cells of the body in response to infection. Recently, L-isoleucine and its analogues have been found to induce antimicrobial peptides. The objectives of the study were to examine if addition of L-isoleucine to oral rehydration salts (ORS) solution would reduce stool output and/or duration of acute diarrhoea in children and induce antimicrobial peptides in intestine. This double-blind randomized controlled trial was conducted at the Dhaka Hospital of ICDDR,B. Fifty male children, aged 6-36 months, with acute diarrhoea and some dehydration, attending the hospital, were included in the study. Twenty-five children received L-isoleucine (2 g/L)-added ORS (study), and 25 received ORS without L-isoleucine (control). Stool weight, ORS intake, and duration of diarrhoea were the primary outcomes. There was a trend in reduction in mean±standard deviation (SD) daily stool output (g) of children in the L-isoleucine group from day 2 but it was significant on day 3 (388±261 vs 653±446; the difference between mean [95% confidence interval (CI) (-)265 (−509, −20); p=0.035]. Although the cumulative stool output from day 1 to day 3 reduced by 26% in the isoleucine group, it was not significant. Also, there was a trend in reduction in the mean±SD intake of ORS solution (mL) in the L-isoleucine group but it was significant only on day 1 (410±169 vs 564±301), the difference between mean (95% CI) (-)154 (-288, −18); p=0.04. The duration (hours) of diarrhoea was similar in both the groups. A gradual increase in stool concentrations of ß-defensin 2 and 3 was noted but they were not significantly different between the groups. L-isoleucine-supplemented ORS might be beneficial in reducing stool output and ORS intake in children with acute watery diarrhoea. A further study is warranted to substantiate the therapeutic effect of L-isoleucine. International Centre for Diarrhoeal Disease Research, Bangladesh 2011-06 /pmc/articles/PMC3131118/ /pubmed/21766553 Text en © INTERNATIONAL CENTRE FOR DIARRHOEAL DISEASE RESEARCH, BANGLADESH http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Papers Alam, N.H. Raqib, R. Ashraf, H. Qadri, F. Ahmed, S. Zasloff, M. Agerberth, B. Salam, M.A. Gyr, N. Meier, R. L-isoleucine-supplemented Oral Rehydration Solution in the Treatment of Acute Diarrhoea in Children: A Randomized Controlled Trial |
title | L-isoleucine-supplemented Oral Rehydration Solution in the Treatment of Acute Diarrhoea in Children: A Randomized Controlled Trial |
title_full | L-isoleucine-supplemented Oral Rehydration Solution in the Treatment of Acute Diarrhoea in Children: A Randomized Controlled Trial |
title_fullStr | L-isoleucine-supplemented Oral Rehydration Solution in the Treatment of Acute Diarrhoea in Children: A Randomized Controlled Trial |
title_full_unstemmed | L-isoleucine-supplemented Oral Rehydration Solution in the Treatment of Acute Diarrhoea in Children: A Randomized Controlled Trial |
title_short | L-isoleucine-supplemented Oral Rehydration Solution in the Treatment of Acute Diarrhoea in Children: A Randomized Controlled Trial |
title_sort | l-isoleucine-supplemented oral rehydration solution in the treatment of acute diarrhoea in children: a randomized controlled trial |
topic | Original Papers |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3131118/ https://www.ncbi.nlm.nih.gov/pubmed/21766553 |
work_keys_str_mv | AT alamnh lisoleucinesupplementedoralrehydrationsolutioninthetreatmentofacutediarrhoeainchildrenarandomizedcontrolledtrial AT raqibr lisoleucinesupplementedoralrehydrationsolutioninthetreatmentofacutediarrhoeainchildrenarandomizedcontrolledtrial AT ashrafh lisoleucinesupplementedoralrehydrationsolutioninthetreatmentofacutediarrhoeainchildrenarandomizedcontrolledtrial AT qadrif lisoleucinesupplementedoralrehydrationsolutioninthetreatmentofacutediarrhoeainchildrenarandomizedcontrolledtrial AT ahmeds lisoleucinesupplementedoralrehydrationsolutioninthetreatmentofacutediarrhoeainchildrenarandomizedcontrolledtrial AT zasloffm lisoleucinesupplementedoralrehydrationsolutioninthetreatmentofacutediarrhoeainchildrenarandomizedcontrolledtrial AT agerberthb lisoleucinesupplementedoralrehydrationsolutioninthetreatmentofacutediarrhoeainchildrenarandomizedcontrolledtrial AT salamma lisoleucinesupplementedoralrehydrationsolutioninthetreatmentofacutediarrhoeainchildrenarandomizedcontrolledtrial AT gyrn lisoleucinesupplementedoralrehydrationsolutioninthetreatmentofacutediarrhoeainchildrenarandomizedcontrolledtrial AT meierr lisoleucinesupplementedoralrehydrationsolutioninthetreatmentofacutediarrhoeainchildrenarandomizedcontrolledtrial |